Bloomwell CEO Responds to Germany’s Cannabis Act Report: “No Reasons to Restrict the Law”
Germany’s progressive Cannabis Act (CanG) is under the microscope. This week, the EKOCAN (Evaluation des Konsumcannabisgesetzes), a research project commissioned by the Federal Ministry of Health, released its first interim report analyzing the impact of the country’s cannabis legalization. The evaluation focuses on three central areas: child and youth protection, public health, and cannabis-related crime.
While the data paints a largely positive picture, the Ministry of Health has simultaneously announced plans to tighten access to medical cannabis. Proposed restrictions include banning mail-order dispensing and requiring in-person consultations for patients. Officials argue that telehealth services are being abused—an argument expected to resurface in the Cabinet’s October 8 review of the Medical Cannabis Act.
Bloomwell Group Pushes Back
As Germany’s largest digital medical cannabis platform—connecting patients, physicians, pharmacies, and wholesalers—Bloomwell Group has emerged as a leading voice in the debate. CEO Niklas Kouparanis issued a statement emphasizing that the evaluation contradicts many of the fears once used to oppose legalization.
“The evaluation of Germany’s Cannabis Act shows that the major fears have not materialized: the number of traffic accidents is not increasing, nor are the number of irregularities in traffic. Consumption among young people is actually declining, and the law is not causing an increase in consumption among adults. On the other hand, crime is decreasing because consumers and patients finally have legal sources of supply, and above all, these people are no longer criminalized.”
Kouparanis warned that restricting the Medical Cannabis Act would roll back hard-won progress:
“There are no reasons to make the law more restrictive, especially with regards to medical cannabis, which is a burgeoning success and now serving thousands of patients in need. The data also shows that the sole consequence of tightening the Medical Cannabis Act would be the re-criminalization of hundreds of thousands of patients – and that public health, as well as the judiciary and police, would benefit from the current legal situation. It is baffling to me that the legislature wants to restrict the Medical Cannabis Act without giving the law its own scientific review – and to return sick people to the system based on a 'perceived' abuse, in reality completely arbitrarily and purely for ideological reasons.”
The Road Ahead
With Germany now a global model for cannabis reform, the EKOCAN report will influence not just national policy but European and international markets. The Cabinet’s upcoming October 8 review will be a crucial moment: policymakers must weigh scientific evidence against political ideology, and decide whether to safeguard access for patients—or restrict it in ways that critics argue could undo years of progress.
For Kouparanis and Bloomwell Group, the message is clear: the data supports the current system, and rolling it back would harm patients, strain public health resources, and undermine trust in reform.
